Pre-made Obexelimab benchmark antibody ( Whole mAb, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-383
Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Obexelimab (XmAb 5871) is an anti-CD19 monoclonal antibody that is being developed by Xencor for the treatment of autoimmune disorders including IgG4-related disease, systemic lupus erythematosus and rheumatoid arthritis. Xencor designed the antibody using its XmAb® technology.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus|
|Development Tech||XmAb Antibody Engineering Technology|